Issue 4/2012

  • Can bioeconomy save the planet?

    In this issue:

    • Swiss Biotech Report reveals more investment in sector
    • Danes kick-off psychiatric genomics research hub
    • Wellcome Trust to aid UK biotech with £200m in funding
    • Analytica 2012 in Munich: Update on bioanalytics
    • Janus to commercialise inclusion body drug delivery system
    • Mabion announces IPO on Warsaw Stock Exchange
    • Intratumour heterogeneity challenges biomarker approach

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/4.html

Kurszettel

Alle Kurse

TOP

  • CYTOS (CH)0.23 CHF53.3%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • CO.DON (D)3.40 EUR9.7%

FLOP

  • WILEX (D)0.88 EUR-15.4%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)11.01 USD-13.5%

TOP

  • CO.DON (D)3.40 EUR94.3%
  • BIOTECH PHARMACON (N)17.50 NOK59.1%
  • WILEX (D)0.88 EUR44.3%

FLOP

  • CYTOS (CH)0.23 CHF-92.0%
  • BIONOR PHARMA (N)2.11 NOK-49.0%
  • GW PHARMACEUTICALS (UK)219.50 GBP-39.5%

TOP

  • SILENCE THERAPEUTICS (UK)255.00 GBP6119.5%
  • IXICO (UK)69.50 GBP782.0%
  • PLETHORA (UK)11.00 GBP609.7%

FLOP

  • CYTOS (CH)0.23 CHF-94.4%
  • EVOCUTIS (UK)0.22 GBP-92.7%
  • AGENNIX (D)0.04 EUR-80.0%

No liability assumed, Date: 16.04.2014